Selank Peptide: Anxiolytic Research, BDNF Modulation & Nootropic Applications

For laboratory and research use only. Not for human consumption.

Selank started as an immunology project. The goal was better metabolic stability. What they got was a heptapeptide that crosses into neuroscience territory in ways nobody predicted.

Anxiolytic effects comparable to benzodiazepines. No sedation. No amnesia. No dependence. Plus BDNF modulation, enkephalinase inhibition, and immunomodulatory activity all wrapped into seven amino acids. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is one of those compounds where the mechanism of action section reads like it’s describing four different drugs. But it’s one peptide. And the preclinical data is surprisingly consistent.

What Is Selank? Chemical Identity

Seven amino acids. TKPRPGP. A synthetic regulatory peptide from the tuftsin family.

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
• Molecular Formula: C₃₃H₅₇N₁₁O₉
• Molecular Weight: 751.87 g/mol
• CAS Number: 129954-34-3
• Classification: Synthetic heptapeptide, tuftsin analogue
• Solubility: Freely water-soluble

The first four residues (Thr-Lys-Pro-Arg) are tuftsin — a tetrapeptide that the spleen cleaves from IgG’s Fc region. Adding Pro-Gly-Pro onto the C-terminus did two things. It slowed enzymatic degradation — extending the compound’s active window well beyond what native tuftsin achieves — and it introduced neurotropic properties that the parent peptide simply doesn’t have.

Development History

Late 1990s, early 2000s. Nikolai Myasoedov’s lab at the Institute of Molecular Genetics, Russian Academy of Sciences. The idea: make a tuftsin analogue that’s harder for enzymes to chew apart, keep the immunomodulatory profile, and see what else happens.

What else happened was anxiolytic activity. That makes Selank one of a handful of peptides anywhere in the world with actual regulatory approval as an anxiolytic agent — though it’s still unapproved by the FDA and EMA, and classified as a research compound in most countries.

Both inhibit enkephalin-degrading enzymes. Different core structures, overlapping but distinct downstream effects.

Mechanism of Action: Five Pathways From One Peptide

This is where Selank gets unusual. Most anxiolytics work through one receptor system. Selank hits at least five distinct molecular pathways. That’s not hand-waving — each one has published data behind it.

1. GABA_A Receptor Modulation (Without the Benzo Baggage)

Volkova’s group showed that Selank alters GABA binding at its receptors without competing for the agonist site. Allosteric modulation — changing how the receptor responds to GABA rather than mimicking GABA directly. That’s the same general category as benzodiazepines, but the details matter enormously.

Kasian et al. (PMID: 26847159) went deeper with a transcriptomic study — 84 genes related to neurotransmission, comparing Selank vs. GABA administration. Strong positive correlation in gene expression changes. Selank isn’t just tweaking receptor binding; it’s shifting the entire GABAergic transcription program.

And yet — no sedation. No amnesia. No muscle relaxation. No dependence. That separation of anxiolysis from sedation is rare. And pharmacologically interesting.

2. BDNF and NGF: Neurotrophin Regulation

This might be Selank’s most important mechanism for neuroscience researchers. The protein curve is more complex: a transient dip followed by a sustained rise above baseline. Rapid signaling cascade first, then slower genomic effects that build over time.

Even more interesting: Kolik et al. (PMID: 31625062) showed that Selank doesn’t just raise BDNF blindly. State-dependent modulation. The compound normalizes BDNF toward physiological levels rather than simply cranking it up — and that distinction matters for anyone studying the neurotrophin hypothesis of affective disorders.

For researchers working with other regulatory neuropeptides like DSIP, Selank’s neurotrophin-centric mechanism opens complementary research angles.

3. Enkephalinase Inhibition

Zozulya et al. measured this directly. Selank inhibits the enzymes that break down enkephalins in plasma — and it does so more potently than bacitracin and puromycin, two established peptidase inhibitors. Since enkephalins get torn apart by aminopeptidases, NEP, and ACE within seconds of release, even modest inhibition of those enzymes meaningfully extends how long enkephalins survive to interact with opioid receptors.

But Selank itself doesn’t bind opioid receptors. Meshavkin et al. confirmed this: naloxone blocks Selank’s behavioral effects (indicating opioid system involvement), yet the peptide shows zero competition at δ or μ receptor binding sites. Indirect engagement. That’s a subtle but critical pharmacological distinction.

4. Serotonin and Dopamine

Nadorova et al. found Selank’s serotonergic effects are state-dependent. Normal baseline conditions? Not much change in 5-HT or 5-HIAA. But when serotonin is pathologically elevated? Selank normalizes accumulation in frontal cortex, hypothalamus, and amygdala. It’s a modulator, not a simple up- or down-regulator.

On the dopamine side, that same Kasian transcriptomic study (PMID: 26847159) caught something specific: Selank activates Drd5 gene expression — dopamine receptor D5. Molecular basis for the nootropic effects that behavioral testing has been documenting.

5. Immunomodulation (The Tuftsin Legacy)

Selank didn’t forget where it came from.

That neuroimmune crossover is what makes Selank unique among anxiolytic research compounds. Most anxiety drugs don’t touch the immune system.

Preclinical Results

Kozlovskaya et al. (2003): 300 μg/kg in rats. %. Vertical activity up 10.2%. Hole investigations up 23.0%. Selank does the opposite.

Semenova et al. Not just one paradigm. Broad-spectrum anxiolysis.

Cognition

Simultaneous anxiolytic and nootropic effects — both driven, apparently, by BDNF modulation and D5 receptor activation.

Versus Benzodiazepines

The head-to-head data against medazepam tells the story clearly:

• Sedation: absent with Selank (may relate to its upregulation of hypocretin/Hcrt gene expression — a wakefulness signal)
• Amnesia: absent.
• Dependence and withdrawal: none observed in any preclinical model

For investigators studying CNS-active regulatory peptides, that’s about as clean a comparison as you’ll find.

Alcohol Withdrawal

Chronic ethanol exposure followed by abrupt cessation. Consistent with the compound’s known effects on enkephalin preservation, BDNF normalization, and GABAergic tone. Multiple mechanisms converging on the same withdrawal phenotype.

Safety Profile

What the preclinical and domestic data show:

• No dependence. No withdrawal. Not even a hint in animal models
• No antibody formation — immunogenicity testing came back clean
• Fast clearance: metabolized in the liver, excreted renally. Gone from circulation in about 10 minutes. Low accumulation risk

Important caveat: most published safety data comes from Russian research institutions. Independent international replication is limited. Researchers should weigh that when designing protocols and interpreting findings.

Regulatory Status

Russia: Approved. One of the few peptide anxiolytics with any regulatory approval worldwide.

United States: Not FDA-approved. Research compound only. Not available for compounding under current guidance.

EU/International: Not EMA-approved. Generally classified as a research compound.

Availability

Loti Labs carries Selank 10mg ($49.99) — lyophilized, ≥98% purity, third-party HPLC and mass spec verified.

Conclusion

A tuftsin analogue that became an anxiolytic. BDNF regulation that normalizes rather than just elevates. Enkephalinase inhibition that preserves endogenous opioid signaling without touching opioid receptors directly. Serotonin and dopamine modulation. Immunomodulatory activity.

Five pathways from seven amino acids.

For laboratory and research use only. Not for human consumption.

References

1. Kasian A, Kolomin T, Andreeva L, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2017;8:782. PMID: 26847159
2. Kolik LG, Nadorova AV, Antipova TA, et al. Bull Exp Biol Med. 2019;167(5):641-644. PMID: 31625062
3. Zozulya AA, Kost NV, Sokolov OY, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-317.
4. Meshavkin VK, Kost NV, Sokolov OY, et al. Selank action on opioid system is mediated by enkephalinase inhibition. Bull Exp Biol Med. 2006;142(5):575-577.
5. Seredenin SB, Kozlovskaya MM, Blednov YA, et al. Zh Vyssh Nerv Deiat Im I P Pavlova. 1998;48(1):153-160.
6. Kozlovskaya MM, Kozlovskii II, Val’dman EA, Seredenin SB. Neurosci Behav Physiol. 2003;33(9):853-860.
7. Seredenin SB, Blednov YA, Badyshtov BA, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096
8. Uchakina ON, Uchakin PN, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75.